In a phase II randomised trial in untreated metastatic pancreatic cancer, adding the TGFβ antibody NIS793 to nab-paclitaxel/gemcitabine suppressed TGFβ signalling and remodelled stroma but did not improve PFS or OS (OS HR 1.32, 95% CI 0.84–2.07).
RCT
Pelletier et al. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study